Wockhardt receives QIDP status for its new drug WCK 4873

From USFDA

Wockhardt announced that United State Food & Drug Administration has granted WCK 4873, a product from their New Drug Discovery Program, Qualified Infectious Disease Product (QIDP) status. This it the third product from Wockhardt to receive this coveted status after WCK 771 and WCK 2349 last year and provides a strong boost to its drug development program.

Powered by Capital Market - Live News